LILRA2 (Leukocyte immunoglobulin like receptor A2), also known as CD85H and LIR7 (Leukocyte immunoglobulin-like receptor 7), is a member of the leukocyte immunoglobulin (Ig)-like receptor (LIR) family of the Ig superfamily (IgSF).  LIR family members are known to have activating and inhibitory functions in leukocytes.  It belongs to the subfamily A class of LIR receptors (LILRAs), which are single-pass type I transmembrane proteins with 2-4 extracellular Ig-like domains, a transmembrane domain (TM), and a short cytoplasmic tail.  LILRA2 contains 4 Ig-like C2 type domains in the extracellular region. LILRA2 does not bind class I MHC antigens. LILRA2 is expressed predominantly on monocytes and B cells, and at lower levels on dendritic cells and natural killer cells. LILRA2 is an activating receptor that inhibits dendritic cell differentiation and antigen presentation and suppresses innate immune response. 

LILRA2 (Leukocyte immunoglobulin like receptor A2), also known as CD85H and LIR7 (Leukocyte immunoglobulin-like receptor 7), is a member of the leukocyte immunoglobulin (Ig)-like receptor (LIR) family of the Ig superfamily (IgSF).  LIR family members are known to have activating and inhibitory functions in leukocytes.  It belongs to the subfamily A class of LIR receptors (LILRAs), which are single-pass type I transmembrane proteins with 2-4 extracellular Ig-like domains, a transmembrane domain (TM), and a short cytoplasmic tail.  LILRA2 contains 4 Ig-like C2 type domains in the extracellular region. LILRA2 does not bind class I MHC antigens. LILRA2 is expressed predominantly on monocytes and B cells, and at lower levels on dendritic cells and natural killer cells. LILRA2 is an activating receptor that inhibits dendritic cell differentiation and antigen presentation and suppresses innate immune response. 

 

Product Details

 

Gene Symbol: LILRA2; LIR7; CD85H; LIR-7; ILT1; ILT-1

 

NCBI Gene ID: 11027

 

Uniprot Entry: Q8N149

 

Construct Details: The recombinant human LILRA2 ECD protein is expressed as an 654-amino acid protein consisting of Gly24 -  Asn449 region of LILRA2 and a C-terminal Fc from human IgG1, which exists as a dimer under non-reducing conditions. LILRA22 ECD contains 7 potential N-linked glycosylation sites.

 

Source: Human cells stably expressing LILRA2-Fc and growing in chemical-defined media with no animal component or antibiotics

 

Deduced Amino Acid Sequence: 

        10         20         30         40         50         60 

GHLPKPTLWA EPGSVIIQGS PVTLRCQGSL QAEEYHLYRE NKSASWVRRI QEPGKNGQFP  

        70         80         90        100        110        120 

IPSITWEHAG RYHCQYYSHN HSSEYSDPLE LVVTGAYSKP TLSALPSPVV TSGGNVTLQC  

       130        140        150        160        170        180 

VSQVAFDGFI LCKEGEDEHP QRLNSHSHAR GWSWAIFSVG PVSPSRRWSY RCYAYDSNSP 

       190        200        210        220        230        240 

YVWSLPSDLL ELLVPGVSKK PSLSVQPGPM VAPGESLTLQ CVSDVGYDRF VLYKEGERDF 

       250        260        270        280        290        300 

LQRPGWQPQA GLSQANFTLG PVSPSHGGQY RCYSAHNLSS EWSAPSDPLD ILITGQFYDR 

       310        320        330        340        350        360 

PSLSVQPVPT VAPGKNVTLL CQSRGQFHTF LLTKEGAGHP PLHLRSEHQA QQNQAEFRMG 

       370        380        390        400        410        420 

PVTSAHVGTY RCYSSLSSNP YLLSLPSDPL ELVVSEAAET LSPSQNKTDS TTTSLGQHPQ 

       430        440        450        460        470        480 

DYTVENSTGT HTCPPCPAPE LLGGPSVFLF PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV 

       490        500        510        520        530        540 

KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE 

       550        560        570        580        590        600 

KTISKAKGQP REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 

       610        620        630        640        650 

TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK

 

  

M.W.: Calculated molecular mass (kDa): 72.5; Estimated by SDS-PAGE under reducing condition (kDa): ~85-90

 

Calculated PI: 6.40

 

Calculated extinction coefficients (M-1 cm-1, at 280nm):  115585

  

Purity: >95% judged by SDS-PAGE under reducing condition (see the gel image above, labeled as "S")

 

Formulation: Supplied at 0.5 mg/ml in sterile PBS pH7.4 (carrier & preservative free)

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method

 

Biological Activity: Not available

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 6 months. 

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

 

 

 

Additional supporting documents, including PDS, COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.